DEP the path to money?, page-5

royalty rates from bell potter for docetaxel and cabaziraxel seem to high and not Aligned with normal rates for drug delivery agents of generic drugs. Those rates are more for new drugs. Maybe argue could apply to dep- sn38 but highwr risk with unapproved drug like sn-38 and needs more supporting data for approval - for safe and effective- Even though it’s is metabolites and bypass liver metabolism.

sales will determine by how much safer and better than existing drug and so far we not have strong evidence just a few case studies and some interim promising data without stats.